The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1620
ISSUE1620
March 22, 2021
Drugs for Multiple Sclerosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Multiple Sclerosis
March 22, 2021 (Issue: 1620)
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for...more
- A Rae-Grant et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:777.
- MP McGinley et al. Diagnosis and treatment of multiple sclerosis: a review. JAMA 2021; 325:765.
- Peginterferon beta-1a (Plegridy) for multiple sclerosis. Med Lett Drugs Ther 2015; 57:67.
- KM Hakkarainen et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord 2020 October 7 (epub).
- A Boster et al. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2011; 4:319.
- PK Coyle. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord 2016; 9:198.
- Natalizumab (Tysabri) for relapsing multiple sclerosis. Med Lett Drugs Ther 2005; 47:13.
- CH Polman et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899.
- PS Sørensen et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18:143.
- AQ Reuwer et al. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy. Acta Neurol Scand 2017; 136(Suppl 201):37.
- In brief: Natalizumab (Tysabri) returns. Med Lett Drugs Ther 2006; 48:76.
- N Ebrahimi et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015; 21:198.
- JD Triplett et al. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. Mult Scler Relat Disord 2020; 40:101961.
- AI Ciplea et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2020; 7:e723.
- E Portaccio et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks. Neurology 2018; 90:e823.
- R Matro et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology 2018; 155:696.
- E Fogarty et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Mult Scler Relat Disord 2016; 9:23.
- S Almas et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int 2016 February 4 (epub).
- Ocrelizumab (Ocrevus) for MS. Med Lett Drugs Ther 2017; 59:98.
- Ofatumumab (Kesimpta) for multiple sclerosis. Med Lett Drugs Ther 2020; 62:203.
- SL Hauser et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376:221.
- SL Hauser et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020; 383:546.
- X Montalban et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376:209.
- JS Wolinsky et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2020; 19:998.
- CG Chisari et al. Rituximab for the treatment of multiple sclerosis: a review. J Neurol 2021 January 8 (epub).
- SL Hauser et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676.
- P Alping et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; 79:950.
- VM Rivera et al. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol 2013; 13:80.
- Oral fingolimod (Gilenya) for multiple sclerosis. Med Lett Drugs Ther 2010; 52:98.
- Siponimod (Mayzent) – a new drug for multiple sclerosis. Med Lett Drugs Ther 2019; 61:70.
- Ozanimod (Zeposia) for multiple sclerosis. Med Lett Drugs Ther 2020; 62:132.
- JA Cohen et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402.
- L Kappos et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391:1263.
- G Comi et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 2019; 18:1009.
- JA Cohen et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 2019; 18:1021.
- RL Woosley et al. QT drugs list. Available at: www.crediblemeds. org. Accessed March 4, 2021.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2020 September 10 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Cladribine (Mavenclad) for multiple sclerosis. Med Lett Drugs Ther 2019; 61:118.
- G Giovannoni et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362:416.
- R Hermann et al. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet 2019; 58:283.
- RJ Fox et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087.
- Dimethyl fumarate (Tecfidera) for multiple sclerosis. Med Lett Drugs Ther 2013; 55:45.
- RT Naismith et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs 2020; 34:185.
- AI Ciplea. Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord 2020 October 31 (epub).
- C Louapre et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 2020; 77:1079.
- M Farez et al. Practice guideline update summary: vaccinepreventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2019; 93:584.
- National Multiple Sclerosis Society. Timing MS medications with COVID-19 mRNA vaccines. Available at: http://bit.ly/3sN8MDq. Accessed March 4, 2021.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Multiple Sclerosis
Article code: 1620b
Article code: 1620b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.